A Prospective, Randomized, Open, Active-controlled, Interventional, Exploratory, Phase II Trial to Evaluate the EBA, Safety and PK of Orally Administered LCB01-0371 in Adult Patients With Smear-positive Pulmonary Tuberculosis

Study Director
T.S. Sim, M.D., Ph.D
Start Date
6 / 2017
Trial Phase
Phase II
Trial Status
Current Enrollment
48 August 2018
Target Enrollment

This trial concluded and a published:

This study is designed to explore antituberculosis of LCB01-0371 through the assess of the early bactericidal activity, safety of administration.


  • Drug: LCB01-0371 800mg, QD
  • Drug: LCB01-0371 400mg, BID
  • Drug: LCB01-0371 800mg, BID
  • Drug: Tubes 3~5Tablet, QD
  • Drug: Zyvox 600mg, BID
  • Drug: LCB01-0371 1200mg, QD
Developer Associations
Compound Associations